Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

657
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
657
Acne Infection01:27

Acne Infection

58
Acne is a multifactorial skin condition primarily affecting adolescents and young adults, with a global prevalence estimated to exceed 75% in this demographic. The condition is characterized by the formation of comedones (blackheads and whiteheads), papules, pustules, nodules, and, in severe cases, cysts, particularly in areas rich in sebaceous glands such as the face, neck, chest, and back. The pathogenesis involves increased sebum production, follicular hyperkeratinization, colonization by...
58
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

698
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
698
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids01:25

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

2.0K
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Author Correction: Atopic dermatitis.

Nature reviews. Disease primers·2026
Same author

The Atopic Dermatitis Shared Decision-Making Tool: Implementing the AHEAD Approach in Clinical Practice.

Journal of cutaneous medicine and surgery·2026
Same author

Refractory linear IgA dermatosis in childhood: a successful response to rituximab.

Anais brasileiros de dermatologia·2026
Same author

The Lancet Commission on Skin Health: aligning with WHO priorities.

Lancet (London, England)·2026
Same author

Comment on 'Two cases of drug-induced psoriasis from second-generation androgen receptor blockers' and two additional cases supporting an emerging drug reaction.

Clinical and experimental dermatology·2025
Same author

Bullous pemphigoid: epidemiological, clinical, and therapeutic analysis of 189 patients in a tertiary center in Brazil.

Anais brasileiros de dermatologia·2025

Related Experiment Video

Updated: Apr 7, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.6K

Topical tacrolimus for atopic dermatitis.

Jade Cury Martins1, Ciro Martins, Valeria Aoki

  • 1Department of Dermatology, Universidade Federal de São Paulo, Wagih Assad Abdalla 172, São Paulo, São Paulo, Brazil, 05651-020.

The Cochrane Database of Systematic Reviews
|July 2, 2015
PubMed
Summary
This summary is machine-generated.

Topical tacrolimus, a calcineurin inhibitor, is effective for moderate to severe atopic dermatitis (AD). Tacrolimus 0.1% outperformed low-potency corticosteroids and pimecrolimus, while tacrolimus 0.03% was superior to mild corticosteroids.

More Related Videos

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.7K
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.8K

Related Experiment Videos

Last Updated: Apr 7, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

17.6K
The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.7K
Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach
09:32

Resolving Water, Proteins, and Lipids from In Vivo Confocal Raman Spectra of Stratum Corneum through a Chemometric Approach

Published on: September 26, 2019

7.8K

Area of Science:

  • Dermatology
  • Immunology
  • Pharmacology

Background:

  • Atopic dermatitis (AD) is a chronic inflammatory skin condition impacting quality of life.
  • Topical corticosteroids (TCS) are first-line AD treatment but have chronic use side effects.
  • Topical tacrolimus is a calcineurin inhibitor (TCI) offering a potential alternative therapy.

Purpose of the Study:

  • To evaluate the efficacy and safety of topical tacrolimus for moderate to severe atopic dermatitis.
  • To compare topical tacrolimus against other active treatments for AD.

Main Methods:

  • Systematic review of randomized controlled trials (RCTs) up to June 2015.
  • Included participants with moderate to severe AD (children and adults).
  • Assessed physician and participant self-assessment of improvement, and adverse effects.

Main Results:

  • Tacrolimus 0.1% showed superiority over low-potency TCS, pimecrolimus 1%, and tacrolimus 0.03%.
  • Tacrolimus 0.03% was more effective than mild TCS and pimecrolimus.
  • Burning was a more frequent side effect with TCIs, but serious adverse events were rare and transient.

Conclusions:

  • Topical tacrolimus, particularly the 0.1% formulation, is an effective treatment for moderate to severe AD.
  • Both tacrolimus formulations demonstrated a favorable safety profile with no evidence of increased malignancy risk or skin atrophy.
  • Further research is needed due to limited data, necessitating cautious interpretation of findings.